Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 14/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29718518 | 0.76 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL29718320 | 0.73 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL29718688 | 0.73 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL11972373 | 0.71 | HCAR2 (1.00) | HCAR2SLC6A4 | |
| SCHEMBL30236770 | 0.71 | HCAR2 (1.00) | HCAR2SLC6A4 | |
| SCHEMBL29718650 | 0.71 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL30102881 | 0.70 | HCAR2 (0.60) | HCAR2SLC6A4CNR2CNR1 | |
| SCHEMBL29718511 | 0.70 | CNR2 (0.63) | CNR2CNR1GSK3BKCNH2 | |
| SCHEMBL29718669 | 0.70 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL29718473 | 0.70 | CNR2 (0.63) | CNR2CNR1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201633-B2 | Compounds and methods for treatment of visceral pain | ARENA PHARMACEUTICALS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201633-B2 | Compounds and methods for treatment of visceral pain | VIP, FABP2, FABP6 | HCAR2 297/4885SLC6A4 3386/4885CNR2 100/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | HCAR2 297/4885SLC6A4 3386/4885CNR2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.